# Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)

> **NCT01450124** · PHASE2 · COMPLETED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 29 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Boswellic acids (BOSWELAN)

## Key facts

- **NCT ID:** NCT01450124
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01450124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01450124, "Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01450124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*